Jane Street Group LLC Buys 16,374 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Jane Street Group LLC raised its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 103.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,129 shares of the biopharmaceutical company’s stock after purchasing an additional 16,374 shares during the period. Jane Street Group LLC owned 0.07% of Puma Biotechnology worth $82,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PBYI. Bank of New York Mellon Corp grew its stake in shares of Puma Biotechnology by 63.6% in the second quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock worth $1,007,000 after acquiring an additional 120,104 shares during the last quarter. Rhumbline Advisers grew its position in Puma Biotechnology by 2,309.9% during the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 48,184 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Puma Biotechnology during the 2nd quarter valued at about $54,000. American Century Companies Inc. raised its holdings in Puma Biotechnology by 98.5% in the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after buying an additional 366,653 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Puma Biotechnology by 6.6% in the second quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock worth $1,975,000 after buying an additional 37,684 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Insider Activity

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the sale, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the transaction, the chief executive officer now owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their position. The disclosure for this sale can be found here. Insiders own 23.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Monday, December 23rd.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $3.07 on Thursday. Puma Biotechnology, Inc. has a one year low of $2.22 and a one year high of $7.73. The stock has a 50-day moving average of $3.06 and a 200 day moving average of $2.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The company has a market capitalization of $150.70 million, a price-to-earnings ratio of 6.40 and a beta of 1.10.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the previous year, the business posted $0.12 earnings per share. On average, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.